PBS Changes from 1 March 2025

Please find below information relating to new and amended Pharmaceutical Benefits Scheme (PBS) listings implemented on 1 March 2025.

The information below relates to the administration of these listings by Services Australia. For further information, please download the Frequently Asked Questions. For information on broader PBS changes, please visit the PBS website. Relevant information and authority application forms have been updated and can be accessed through the Services Australia website.

Severe Crohn's disease; moderate to severe ulcerative colitis; severe active juvenile idiopathic arthritis; complex refractory fistulising Crohn's disease; severe active rheumatoid arthritis; severe psoriatic arthritis; ankylosing spondylitis; severe chronic plaque psoriasis; moderate to severe hidradenitis suppurativa; vision threatening non-infectious uveitis 

Adalimumab (80 mg/0.8 ml injection, 0.8 ml pen device) (Hyrimoz®) is a new strength of biosimilar now listed on the PBS for the treatment of severe Crohn's disease; moderate to severe ulcerative colitis; severe active juvenile idiopathic arthritis; complex refractory Fistulising Crohn's disease; severe active rheumatoid arthritis; severe psoriatic arthritis; ankylosing spondylitis; severe chronic plaque psoriasis; moderate to severe hidradenitis suppurativa; vision threatening non-infectious uveitis. 

Precursor B-cell acute lymphoblastic leukaemia (Pre-B-cell ALL) 

Blinatumomab (38.5 microgram injection [1 vial](&) inert substance solution [10 ml vial], 1 pack) 
(Blincyto®) is now listed on the PBS for the treatment of Pre-B-cell ALL. Authority applications for initial and grandfather treatments can be made in writing. Applications for continuing treatment can be made either in real-time using the Online PBS Authorities system or by telephone. 

Retinal vein occlusion 

Faricimab (6 mg/0.05 ml intraocular injection, 0.05 ml vial) (Vabysmo®) is now listed on the PBS for the treatment of branch or central retinal vein occlusion with macular oedema. Authority applications for initial treatment can be made either in real-time using the Online PBS Authorities system or in writing. Prescriptions for continuing treatment are Authority required (STREAMLINED). 

Severe psoriatic arthritis 

Risankizumab (150 mg/ml injection, 1 ml pen device) (Skyrizi®) is now listed on the PBS for the treatment of severe psoriatic arthritis. Authority applications for initial, grandfather and continuing treatments can be made in writing. 

Endogenous Cushing's syndrome 

Osilodrostat (1 mg tablet; 5 mg tablet) (lsturisa®) is now listed on the PBS for the treatment of endogenous Cushing's syndrome. Authority applications for initial, grandfather and continuing treatments can be made either in real-time using the Online PBS Authorities system or by telephone. 

Multiple sclerosis 

Fingolimod (250 microgram capsule; 500 microgram capsule) (Gilenya®); ofatumumab (20 mg/0.4 ml injection, 0.4 ml pen device) (Kesimpta®); siponimod (250 microgram tablet; 1 mg tablet; 2 mg tablet) 
(Mayzent®) has had an amendment to the listing to allow prescribing by nurse practitioners in consultation with a specialist physician. Prescriptions for treatment are Authority required 
(STREAM LI NED). 

Non-familial hypercholesterolaemia & familial heterozygous hypercholesterolaemia 

lnclisiran (284 mg/1.5 ml injection, 1.5 ml syringe) (Leqvio®) has had an amendment to the restriction level. Prescriptions for treatment are now Authority required (STREAMLINED). There has also been an amendment to the listing to allow prescribing by nurse practitioners in consultation with a specialist physician.